Our Story: Unlocking a new dimension of transformative genomic discovery

Phase Genomics was founded with the mission of maximizing the impact of genomics on society. With the vast majority of biological information remaining un-explored, we seek to empower researchers to make breakthrough discoveries using the power of advanced, next-generation genomic tools. The cornerstone of our approach lies in a technology called proximity ligation, which enables unprecedented improvements in the depth and quality of information generated from DNA sequencing efforts. From tracking viruses and their targets to detecting chromosomal abnormalities in oncology samples, our molecular and computational tools add a new dimension to genomic information. By continuously developing new genomic methods, we seek to bring transformative change to research, industry, and the clinic.

Phase Genomics leverages ultra-long-range sequencing technology to enable genomic profiling, microbiome discovery, and genome assembly. We offer a comprehensive portfolio of laboratory and computational services and products. These include proximity ligation (Hi-C) kits for plants, animals, microbes, and human samples, as well as industry-leading software for genome, metagenome, and structural variant analysis. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company's mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

Ivan Liachko

Founder & CEO

Dr. Liachko received his Ph.D. at Cornell University in 2007 and has worked in the genetic/genomic research field for over 25 years. He has authored over 50 peer-reviewed papers and created multiple patents specializing in the field of microbial genomics and synthetic biology. He is one of the original inventors of Phase’s core technology and has served as CEO & CSO of Phase Genomics since its founding.

Phase Genomics

Kayla Young

COO

Dr. Young received her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University in 2016 and, since graduation, has worked with biotechnology entrepreneurs. Prior to Phase Genomics, she worked at Life Science WA where she managed entrepreneurial events, educational seminars, and a mentoring program for young start-up companies. It was in her work at LSW that she developed a love for working with startups and solving the ever-changing problems that they face. Kayla has served as Director of Operations, VP of Operations and Chief Operations Officer of Phase Genomics since September 2017.

Phase Genomics

David Shoultz

CBO

David Shoultz received his Ph.D. at the University of Washington (1997) and his M.B.A. at Seattle University (2012).  His career has focused on clinical research, drug development, diagnostics, and global health.  He has special expertise in infectious diseases and epidemiology, but has worked across many different therapeutic areas, including oncology.  In addition to his executive role at Phase Genomics, David is a Non-Executive Director at Proteotype Diagnostics and an Affiliate Professor at the University of Washington Department of Epidemiology.

Phase Genomics
headshot of man

Stephen Eacker

VP of Research & Development

Dr. Eacker received his Ph.D. from the University of Washington Department of Genome Sciences.  Following his post-doctoral fellowship he was promoted to tenure-track faculty in the Institute for Cell Engineering and Department of Neurology at the Johns Hopkins University where he developed novel genomic tools for the dissection of neurological disease.  He embarked on a new direction of genomic technology development when he joined Phase Genomics in 2018 where he currently serves as the head of Research and Development.

Phase Genomics

Advisory Board

Jay Shendure

Jay Shendure, PhD

Co-Founder & Scientific Advisor

Dr. Shendure is an Investigator of the Howard Hughes Medical Institute and Professor of Genome Sciences at the University of Washington. Dr. Shendure's 2005 PhD included one of the first successful demonstrations of massively parallel or next generation DNA sequencing. His research group in Seattle has made significant contributions to technologies including exome sequencing and its application to identify the basis of Mendelian disorders and autism spectrum disorders; genome-wide experimental haplotyping and its application to non-invasive whole genome sequencing of a human fetus; massively parallel reporter assays and saturation genome editing; combinatorial indexing for single cell analyses; and whole organism lineage tracing. He is the recipient of the 2012 Curt Stern Award from the American Society of Human Genetics, the 2013 FEDERAprijs, a 2013 NIH Director's Pioneer Award, and the 2014 HudsonAlpha Life Sciences Prize.

Phase Genomics
Maitreya Dunham

Maitreya Dunham, PhD

Co-Founder & Scientific Advisor

Dr. Dunham is a Fellow of the Howard Hughes Medical Institute and Associate Professor of Genome Sciences at the University of Washington. She specializes in developing and using high-throughput genomic technologies to study the consequences of genetic variation, from single nucleotide changes to whole extra chromosomes. She works primarily in yeast, but has expanded her research scope to also include human genetic variation and metagenomes. She has also consulted for biotech companies seeking to implement the new tools and methods developed in her lab. Maitreya got her BS in biology from MIT, her PhD in genetics with David Botstein at Stanford University, and started her lab as one of the first Lewis-Sigler Fellows at Princeton University before moving to UW Genome Sciences.

Phase Genomics
Elhanen Borenstein

Elhanan Borenstein, PhD

Scientific Advisor

Dr. Borenstein is an Associate Professor of Genome Sciences at the University of Washington, with an adjunct position in the Department of Computer Science and Engineering. He is also an external professor at the Santa Fe Institute for complexity science. Dr. Borenstein received his PhD in computer science from Tel-Aviv University, Israel, and held a joint postdoctoral fellowship at the Department of Biology in Stanford and at the Santa Fe Institute. He also has extensive professional experience in the hi-tech industry, where he held top management positions in several hi-tech companies. Dr. Borenstein integrates metagenomic data with methods inspired by systems biology, network theory, machine-learning, and statistical inference to develop a variety of computational methods for studying the human microbiome. His work focuses on reconstructing predictive, systems-level models of the human microbiome and on integrative, multi-metaomic analysis, aiming to provide a better principled understanding of the microbiome and its role in human health. Dr. Borenstein is the recipient of various awards including, most recently, the Alfred P. Sloan Fellowship and the NIH New Innovator Award.

Phase Genomics
Andrew Adey

Andrew Adey, PhD

Scientific Advisor

Dr. Adey is an Assistant Professor of Molecular and Medical Genetics at Oregon Health and Science University and a member of the Knight Cardiovascular Institute. He completed his Ph.D. in Molecular and Cell Biology at the University of Washington and was a recipient of the Distinguished Dissertation Award and the Harold M. Weintraub Graduate Student Award. Dr. Adey has spent his entire career in technology development in the area of high throughput genomics for which he has authored numerous publications and patents. After receiving his doctorate he formed his independent group at OHSU where his lab has focused on the development and deployment of high throughput single cell epigenetics technologies.

Phase Genomics
Ken Myer

Ken Myer

Business Advisor

Ken Myer has over 25 years of successful experience in the technology industry leading companies ranging in size from startups to Fortune 100. Ken currently serves as an interim executive and advisor to technology companies, particularly those undergoing leadership or organizational transition. He is also a Lecturer at the UW Foster School of Business, teaching classes on Leadership of High Performance Organizations and Technology Commercialization. Ken recently served interim executive roles at HydraMaster, Yapta.com, Data I/O and Tarmac24 and previously, Ken was President and Chief Executive Officer of the Washington Technology Industry Association, one of the largest regional technology trade associations in North America. Ken was Executive Vice President of publicly traded Active Voice Corporation and for fifteen years Ken held a variety of executive positions at IBM including General Manager of the Northwest and Intermountain Region, National Executive for the Computer Services Industries, and CFO IBM Northwest. Ken holds an MBA and M.A. from the University of Washington and is currently on the boards of AnswerDash and Forterra. He has been recognized as one of Seattle’s most influential business leaders by Seattle Magazine.

Phase Genomics
Todd Smith

Todd Smith, PhD

Business Advisor

Dr. Smith is a successful bioinformatics entrepreneur. After receiving his PhD in Medicinal Chemistry, he developed bioinformatics software as his team sequenced the BRCA1 gene under Leroy Hood in collaboration with Mary Claire-King. In 1997 he founded Geospiza and led the development of LIMS and high throughput data analysis systems for DNA sequencing and microarray technologies. PerkinElmer acquired Geospiza in 2011 and in 2013 Dr. Smith joined Digital World Biology. In 2015 Dr. Smith co-founded Koan AgroScience where he serves in the role of Chief Science and Technology Officer. Dr. Smith has published in multiple disciplines including chemistry, computer science, genetics/genomics, microbiology, human health, and education. Dr. Smith also serves as an entrepreneur mentor for the University of Washington’s CoMotion business incubator. In that role, he works with emerging businesses to perform market assessments for different technologies in genomics and bioinformatics.

Phase Genomics

2024 Events

Interested in joining our team?
View Openings